English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 5 November 2012, 16:50 HKT/SGT
Share:
    

Source: INC Research, LLC
INC Research Discusses Benefits of Involving CROs Early in Planning at Partnerships in Clinical Trials 2012
Global CRO Offers Ways to Accelerate Pipeline Success through Innovation, Early Involvement

Camberley, UK, Nov 5, 2012 - (ACN Newswire) - INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, will discuss the importance of involving CROs early in the planning process at the Partnerships in Clinical Trials conference, November 6-9, 2012 at the CCH Congress Center in Hamburg, Germany. Visit Booth #709 where INC Research executives will be on site to discuss how drug developers can identify the right strategic alliance model to meet their outsourcing needs and ensure the best chance of success in bringing their products to market.

"We're excited to be taking part again in this year's Partnerships in Clinical Trials," said Alistair Macdonald, President, Clinical Development Services, and head of the Company's European operations. "Europe continues to be an important region for clinical research, particularly in the areas of oncology, CNS, cardiology, and endocrinology, which are currently experiencing significant growth in the region. By having locally-based teams with strong regional knowledge of every European country, we can engage our customers earlier in the product lifecycle to offer more insightful strategies that ultimately speed their products to market. And if customers are looking beyond Europe, our global footprint also enables us to deliver high-quality clinical development service anywhere in the world."

The continued shift in the biopharmaceutical company-CRO relationship from project-specific outsourcing to clinical delivery strategic alliances has made it easier for drug developers to benefit from CROs as innovation partners. Multi-year strategic alliances include more input from the CRO and leverage years of perspective, expertise and tactical approaches. These strategic alliances enable CROs to focus more deeply on the commercial and regulatory viability of compounds much earlier in the drug development lifecycle.

INC Research Speaker

INC Research is pleased to once again contribute thought leadership to the agenda for the Partnerships in Clinical Trials conference, with Manfred Weiler, PhD, Senior Vice President, Europe & Asia Pacific Business and Alliance Development presenting on the benefits of involving CROs early in planning. Specifically, he will explore the importance of involving CROs at the pre-protocol stage, how to exploit best practices from a CRO, and how to determine the level of involvement with CROs that works best for individual projects. Dr. Weiler's session, "Benefits of involving your CRO early in planning," will be held on Nov. 7 at 3:45 p.m.

Additionally, INC Research executives will be on hand to discuss recent developments in:

-- Strategic alliances - Evaluate innovative and flexible partnership models that enable customers to quickly and efficiently assess product potential and accelerate their delivery to market.

-- Conducting trials in Europe - Examine the latest considerations and regional nuances for clinical research in fast-growing therapeutic areas like oncology, CNS, cardiovascular, and endocrinology.

-- Metrics-driven methodologies - Achieve high-quality results, including faster study start-up times, patient enrollments and database locks, through globally harmonized standardized operating procedures at every clinical trial stage through our Trusted Process(R), a proprietary approach to clinical development.

-- Data-Driven Intelligence and Decision Making - An innovative approach to data, applied at the patient, study, program and sponsor level, leads to efficiencies in study start-up and patient recruitment and enables a risk-based monitoring approach.

With global experience in more than 100 countries and the extensive therapeutic expertise to work in nearly any indication, INC Research is a leader in developing innovative and flexible strategic alliances that enable customers to quickly and efficiently assess product potential. From full-service strategic partnerships to functional service provider (FSP) alliances, networked drug development to niche solutions tailored to individual customer needs, INC Research can advise customers on the development model that best fits their unique requirements. INC Research has a strong track record in Europe where the Company has run trials in every European country, including those in Central and Eastern Europe.

For more information about INC Research's capabilities for conducting clinical trials in Europe, please visit booth #709 at Partnerships in Clinical Trials or download our European capabilities brochure. Customers interested in contacting INC Research can reach us in Europe at +44 1276 4810000 or at info@incresearch.com .

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process(R) methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.

Contact: Lori Dorer, Media +1-513-345-1685


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE

Topic: Press release summary
Source: INC Research, LLC


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

INC Research, LLC Related News
Nov 7, 2014 08:50 HKT/SGT
INC Research Announces Pricing of Initial Public Offering
Oct 7, 2014 07:10 HKT/SGT
INC Research Files Registration Statement for Initial Public Offering
Oct 3, 2014 10:30 HKT/SGT
INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit
Oct 2, 2014 07:20 HKT/SGT
INC Research Further Reinforces Commitment to Clinical Research Sites and Patients through Creation of New Leadership Role
Aug 6, 2014 03:30 HKT/SGT
INC Research's Tara Fitzgerald and Judy Swilley Named to Annual PharmaVOICE 100
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575